News

MedAvante-ProPhase Research Demonstrates Feasibility of Identifying “Atypical” patterns of CDR Domain Scoring

At 10th Clinical Trials on Alzheimer’s Disease (CTAD) MedAvante-ProPhase presented research and analysis addressing the need to identify administrations of the Clinical Dementia Rating scale (CDR) within clinical trials that have an increased probability of scoring errors to maintain data integrity and improve signal detection.

Continue reading

MedAvante Research Shows Subjective Interview Quality Metrics Can Predict Scoring Performance in PANSS Administration

MedAvante presented research at the 30th European College of Neuropsychopharmacology (ECNP) Congress showing that subjective interview quality metrics are predictive of in-study scoring performance and can serve as a useful tool in ongoing monitoring of raters in the administration and scoring of the PANSS. When combined with eCOA administration to improve standardization, subjective quality metrics can increase signal detection in global schizophrenia clinical trials.

Continue reading

MedAvante Research Demonstrates Impact of Central Review on Outcome Assessments

Research presented at the 2017 International Society for CNS Clinical Trials and Methodology (ISCTM) Fall Conference examined Central Review of two widely used efficacy measures administered in schizophrenia and depression trials, the Positive and Negative Syndrome Scale (PANSS) and Hamilton Depression Rating Scale (HAM-D), resulting in positive impact on individual item scores and total scale score for key study visits, improving interrater reliability and reducing rater drift.

Continue reading

MedAvante Research Suggests RBANS is Suitable Neurocognitive Endpoint in MCI Clinical Trials

The RBANS total scale index score correlated with the CDR-SB, and decreased in a linear fashion with increasing CDR-SB, even within a limited range of CDR-SB scores and without evidence of floor or ceiling effects.

Continue reading

MedAvante Presents Data Showing Impact of Lag Time on Error Rates for Alzheimer’s Clinical Outcome Assessments (COA)

Research presented at 2017 Alzheimer’s Association International Conference (AAIC) demonstrates that increased lag time between administrations of COAs significantly increases error rates on three of the most commonly used and complex measures in AD clinical trials.

Continue reading

MedAvante presents new research on Schizophrenia trials at American Society of Clinical Psychopharmacology (ASCP)

Analysis provides additional evidence of substantial agreement between PANSS total score and CGI-S rating; brings into question the additional value of CGI-S administration in view of its limitations including expectancy bias, ceiling effects, and lack of reliability data.

Continue reading

U. of Chicago Booth School Presents Distinguished Alumni Award to Amy Ellis

Prestigious Award Recognizes Outstanding Professional Achievement

Hamilton, NJ (May 2, 2017) — MedAvante, Inc., the leading global clinical data services company dedicated to maximizing signal detection in clinical trials, announced that Amy Ellis, president and co-founder, has been selected to receive the Distinguished Alumni Award (DAA) from the University of Chicago Booth School of Business.

Araclon Biotech Selects MedAvante Virgil Platform for Phase 2 Alzheimer’s Trial

Shared Goal Is Improving Signal Detection and Data Quality through Standardization

Zaragoza, Spain and Hamilton NJ, USA (March 30, 2017) — Araclon Biotech, a Grifols company dedicated to the research and development of therapies and diagnostic methods to be applied to degenerative diseases, and MedAvante, Inc., the leader in technology-based clinical trial services for central nervous system (CNS) diseases, today announced that Araclon Biotech has selected MedAvante’s groundbreaking Virgil® Investigative Study Platform for its upcoming Phase 2 trial in prodromal or very mild Alzheimer’s disease (AD).

MedAvante Names Ropacki Head of Research and Development

Accomplished Clinical Scientist Will Accelerate Company’s Growth

Hamilton, NJ (February 22, 2017) — MedAvante, Inc., the leading global clinical data services company dedicated to maximizing signal detection in clinical trials, announced that Michael T. Ropacki, PhD, has been appointed Vice President, Research and Development to lead the company’s continued expansion of clinical science and signal detection capabilities.

Ian Neilson Joins MedAvante As Global IT Leader

Former Covance Executive Is Accomplished Technology Innovator

Hamilton, NJ (February 8, 2017) — MedAvante, Inc., the leading global clinical data services company dedicated to maximizing signal detection in clinical trials, announced that Ian C. Neilson has accepted the position of Senior Vice President, Global Information Technology to lead the company’s rapidly growing IT operations supporting clinical science and signal detection capabilities.